Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Zimran Discusses Gaucher Disease Biomarkers

January 26th 2012

Dr. Ari Zimran, from Shaare Zedek Medical Center, Jerusalem, Discusses Biomarkers in Gaucher Disease

Nonmyeloablative Conditioning Before Cell Transplantation Shows Potential in Older Patients With Hematologic Malignancies

January 26th 2012

Older patients with advanced hematologic malignancies who receive a minimally toxic nonmyeloablative regimen before allogeneic HCT have favorable OS and PFS rates.

FDA Approves Genzyme's Fabrazyme Plant

January 24th 2012

Genzyme Corporation announced that the FDA has approved its new manufacturing plant in Framingham, Massachusetts.

Dr. Berenson Discusses Early Phase Proteasome Inhibitors

January 24th 2012

Dr. James Berenson, from the Institute for Myeloma and Bone Cancer Research, Discusses Early Phase Proteasome Inhibitors

Bortezomib Approved for Subcutaneous Injection

January 24th 2012

The FDA has deemed subcutaneous injection as a safe and valid method of delivering the drug bortezomib in patients with multiple myeloma.

A Dog Named George: Rx for Recovery

January 24th 2012

While she attributes her survival to her oncologists and the care they provided, Maryclaire is quick to stress the difference between surviving and living, noting that it was her friends and family who gave her what she needed to truly recover.

Rituximab for Chronic Lymphocytic Leukemia in Treatment-Naïve and Treatment-Experienced Patients

January 23rd 2012

A mixed treatment comparison demonstrated that FCR significantly prolonged PFS compared with all other treatments and significantly increased ORR compared with all other treatments.

Dr. O'Brien Discusses the Standard of Care for CLL

January 22nd 2012

Dr. Susan O'Brien, from the MD Anderson Cancer Center, Discusses the Standard of Care for CLL

Dr. Cappellini on Splenectomy in Gaucher Disease Patients

January 20th 2012

Dr. Maria Cappellini, Maggiore Hospital, Milan, Italy, on Splenectomy in Gaucher Disease Patients.

FDA Issues New Safety Warnings on Brentuximab, Including Risk of Rare Brain Infection

January 13th 2012

The FDA and Seattle Genetics announced that new warning labels would be issued for brentuximab vedotin.

Hematologic Congress Spotlights Major Issues, Emerging Research

January 13th 2012

Several advancements in research and drug approvals have changed the landscape of care for optimal treatment in patients with lymphoma, leukemia, and myeloma.

FISH Testing Guides Treatment of CLL: New Drugs on Horizon

January 12th 2012

FISH testing for genetic abnormalities is the key to appropriate treatment selection for patients with CLL.

Using Molecular Markers in AML for Prediction, Treatment, and Monitoring

January 5th 2012

Several molecular markers for AML are now used at top-tier cancer centers for prediction, treatment selection, and monitoring response.

New Assays Open Window in Evaluating Leukemia Types

January 5th 2012

Genetic markers are becoming a more integral part of diagnosing cancer and determining which patients will encounter more aggressive forms of their disease.

Dr. Zelenetz Discusses the Winter Hematology Meeting

January 5th 2012

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses the Winter Hematology Meeting

Dr. Lukina Discusses Timely Gaucher Disease Diagnosis

December 24th 2011

Dr. Elena Lukina Discusses Timely Gaucher Disease Diagnosis

Dr. Sehn Discusses the GAUSS Obinutuzumab Trial

December 22nd 2011

Dr. Laurie Sehn, from the British Columbia Cancer Agency, Discusses the GAUSS Obinutuzumab Trial

Dr. Zelenetz Discusses Brentuximab Vedotin

December 22nd 2011

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses Brentuximab Vedotin

Dr. Couriel Discusses Treating GVHD With Photopheresis

December 20th 2011

Dr. Daniel Couriel, from the Unversity of Michigan Comprehensive Cancer Center, Discusses Treating GVHD With Photopheresis

Update on Bone Disease in Multiple Myeloma

December 19th 2011

Bone disease occurs in about 84% of patients with multiple myeloma and is responsible for a great deal of morbidity, including pain, hypercalcemia, compromised quality of life, and pathological fracture.